Lycera Obtains $5,000,000 New Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    2800 Plymouth Rd Ann Arbor, MI 48109
  • Company Description
    Lycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for any additional information, including solicitation if applicable.
  • M&A Terms
  • Venture Investor

By posting a comment, you agree to our terms and conditions.